The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Rifaximin (Xifaxanta®) has been rejected for the treatment of travellers' diarrhoea that is not associated with fever, bloody diarrhoea, 8 or more unformed stools in the previous 24 hours or occult blood or leucocytes in the stool. The manufacturer failed to make a submission.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« BNF for Children 2012-2013||NICE Guidance - August 2012 »|